IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
Phase 3positiveIMDELLTRAIMFINZIPositive
AI Analysis
Summary
Amgen's Phase 3 DeLLphi-305 study demonstrated a landmark overall survival benefit for IMDELLTRA in combination with IMFINZI versus durvalumab alone in first-line extensive stage small cell lung cancer, with secondary endpoints of progression-free survival and objective response rate also met.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
DeLLphi-305 demonstrated highly significant and clinically meaningful overall survival benefit with IMDELLTRA in combination with IMFINZI versus durvalumab alone. Study met secondary endpoints of progression-free survival and objective response rate.
Importance:8/10
Sentiment:
0.90
Phase 3OncologySmall Cell Lung CancerOverall SurvivalCombination TherapyData Readout
Related Companies
Read the original article
Published by PR Newswire Pharma on September 8, 2026 1:00 PM